Treatment outcome according to selected clinical and biologic features
Features . | No. of patients (%) . | No. obtaining complete remission (%) . | 5-year event-free survival in % (SE) . | P value according to Mantel-Haenszel test . |
|---|---|---|---|---|
| Risk | ||||
| Lower | 117 (47.4) | 116 (99.1) | 88.1 (3.8) | .003 |
| Higher | 130 (52.6) | 126 (96.9) | 73.0 (5.5) | |
| NCI/Rome risk (B-lineage ALL) | ||||
| Standard | 112 (55.4) | 111 (99.1) | 87.3 (3.2) | .054 |
| High | 90 (44.6) | 88 (97.8) | 76.7 (4.6) | |
| Age | ||||
| Younger than 1 y | 10 (4.0) | 10 (100) | 70.0 (14.5) | .08 |
| 1 to 10 y | 161 (65.2) | 160 (99.4) | 84.3 (2.9) | |
| Older than 10 y | 76 (30.8) | 72 (94.7) | 74.9 (5.2) | |
| Sex | ||||
| Female | 103 (41.7) | 101 (98.1) | 83.3 (3.8) | .31 |
| Male | 144 (58.3) | 141 (97.9) | 79.1 (3.5) | |
| Race | ||||
| White | 199 (80.6) | 194 (97.5) | 79.3 (3.0) | .45 |
| Black | 45 (18.2) | 45 (100) | 86.5 (5.1) | |
| Other | 3 (1.22) | 3 (100) | 100 (0.0) | |
| Leukocyte count, | ||||
| Lower than 10 × 109/L | 111 (44.9) | 108 (97.3) | 82.7 (3.8) | .02 |
| 10 to 49 × 109/L | 70 (28.3) | 70 (100) | 88.6 (3.9) | |
| 50 to 99 × 109/L | 28 (11.3) | 27 (96.4) | 78.6 (7.8) | |
| 100 × 109/L or higher | 38 (15.4) | 37 (97.4) | 63.0 (7.8) | |
| CNS status | ||||
| CNS-1 + TLP− | 145 (58.7) | 142(97.9) | 81.3 (3.4) | .96 |
| CNS-2 | 78 (31.6) | 76 (97.5) | 80.6 (4.6) | |
| CNS-3 | 7 (2.8) | 7 (100) | 71.4 (15.6) | |
| TLP+ | 17 (6.9) | 17 (100) | 82.4 (9.2) | |
| Immunophenotype | ||||
| B-cell precursor | 202 (82.4) | 199 (98.5) | 82.6 (2.8) | .17 |
| T-cell | 43 (17.6) | 41 (95.3) | 71.9 (6.8) | |
| DNA index | ||||
| 1.16 or more | 46 (18.6) | 45 (97.8) | 91.2 (4.3) | .03 |
| Less than 1.16 | 201 (81.4) | 197 (98.0) | 78.5 (3.0) | |
| t(9;22)/BCR-ABL | ||||
| Absent | 232 (97.1) | 228 (98.3) | 82.6 (2.6) | <.0001 |
| Present | 7 (2.9) | 6 (85.7) | 28.6 (13.9) | |
| t(4;11)/MLL-AF4 | ||||
| Absent | 204 (96.7) | 199 (97.5) | 82.2 (2.8) | .003 |
| Present | 7 (3.3) | 7 (100) | 42.9 (16.2) | |
| t(1;19)/E2A-PBX1 | ||||
| Absent | 201 (95.3) | 196 (97.5) | 81.0 (2.9) | .99 |
| Present | 10 (4.7) | 10 (100) | 80.0 (11.9) | |
| TEL-AML1 | ||||
| Present | 39 (22.7) | 39 (100) | 84.5 (6.2) | .41 |
| Absent | 133 (77.3) | 129 (97.0) | 78.8 (3.7) | |
| Day 19 marrow | ||||
| Less than 5% blasts | 220 (92.4) | 219 (99.6) | 83.5 (2.6) | <.001 |
| 5% or more blasts | 18 (7.6) | 15 (83.3) | 55.6 (11.2) | |
| Minimal residual leukemia on remission date | ||||
| Less than 0.01% | 86 (72.9) | 86 (100) | 84.8 (4.5) | .004 |
| 0.01% or more | 32 (27.1) | 32 (100) | 65.5 (10.3) |
Features . | No. of patients (%) . | No. obtaining complete remission (%) . | 5-year event-free survival in % (SE) . | P value according to Mantel-Haenszel test . |
|---|---|---|---|---|
| Risk | ||||
| Lower | 117 (47.4) | 116 (99.1) | 88.1 (3.8) | .003 |
| Higher | 130 (52.6) | 126 (96.9) | 73.0 (5.5) | |
| NCI/Rome risk (B-lineage ALL) | ||||
| Standard | 112 (55.4) | 111 (99.1) | 87.3 (3.2) | .054 |
| High | 90 (44.6) | 88 (97.8) | 76.7 (4.6) | |
| Age | ||||
| Younger than 1 y | 10 (4.0) | 10 (100) | 70.0 (14.5) | .08 |
| 1 to 10 y | 161 (65.2) | 160 (99.4) | 84.3 (2.9) | |
| Older than 10 y | 76 (30.8) | 72 (94.7) | 74.9 (5.2) | |
| Sex | ||||
| Female | 103 (41.7) | 101 (98.1) | 83.3 (3.8) | .31 |
| Male | 144 (58.3) | 141 (97.9) | 79.1 (3.5) | |
| Race | ||||
| White | 199 (80.6) | 194 (97.5) | 79.3 (3.0) | .45 |
| Black | 45 (18.2) | 45 (100) | 86.5 (5.1) | |
| Other | 3 (1.22) | 3 (100) | 100 (0.0) | |
| Leukocyte count, | ||||
| Lower than 10 × 109/L | 111 (44.9) | 108 (97.3) | 82.7 (3.8) | .02 |
| 10 to 49 × 109/L | 70 (28.3) | 70 (100) | 88.6 (3.9) | |
| 50 to 99 × 109/L | 28 (11.3) | 27 (96.4) | 78.6 (7.8) | |
| 100 × 109/L or higher | 38 (15.4) | 37 (97.4) | 63.0 (7.8) | |
| CNS status | ||||
| CNS-1 + TLP− | 145 (58.7) | 142(97.9) | 81.3 (3.4) | .96 |
| CNS-2 | 78 (31.6) | 76 (97.5) | 80.6 (4.6) | |
| CNS-3 | 7 (2.8) | 7 (100) | 71.4 (15.6) | |
| TLP+ | 17 (6.9) | 17 (100) | 82.4 (9.2) | |
| Immunophenotype | ||||
| B-cell precursor | 202 (82.4) | 199 (98.5) | 82.6 (2.8) | .17 |
| T-cell | 43 (17.6) | 41 (95.3) | 71.9 (6.8) | |
| DNA index | ||||
| 1.16 or more | 46 (18.6) | 45 (97.8) | 91.2 (4.3) | .03 |
| Less than 1.16 | 201 (81.4) | 197 (98.0) | 78.5 (3.0) | |
| t(9;22)/BCR-ABL | ||||
| Absent | 232 (97.1) | 228 (98.3) | 82.6 (2.6) | <.0001 |
| Present | 7 (2.9) | 6 (85.7) | 28.6 (13.9) | |
| t(4;11)/MLL-AF4 | ||||
| Absent | 204 (96.7) | 199 (97.5) | 82.2 (2.8) | .003 |
| Present | 7 (3.3) | 7 (100) | 42.9 (16.2) | |
| t(1;19)/E2A-PBX1 | ||||
| Absent | 201 (95.3) | 196 (97.5) | 81.0 (2.9) | .99 |
| Present | 10 (4.7) | 10 (100) | 80.0 (11.9) | |
| TEL-AML1 | ||||
| Present | 39 (22.7) | 39 (100) | 84.5 (6.2) | .41 |
| Absent | 133 (77.3) | 129 (97.0) | 78.8 (3.7) | |
| Day 19 marrow | ||||
| Less than 5% blasts | 220 (92.4) | 219 (99.6) | 83.5 (2.6) | <.001 |
| 5% or more blasts | 18 (7.6) | 15 (83.3) | 55.6 (11.2) | |
| Minimal residual leukemia on remission date | ||||
| Less than 0.01% | 86 (72.9) | 86 (100) | 84.8 (4.5) | .004 |
| 0.01% or more | 32 (27.1) | 32 (100) | 65.5 (10.3) |
Data missing for some features.
TLP− indicates traumatic lumbar puncture without blasts; TLP+, traumatic lumber puncture with blast.